A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition with Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients with Metastatic Colorectal Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Erlotinib (Primary) ; Panitumumab (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 10 Jan 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2020.
- 10 Jan 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2019.
- 16 Jun 2016 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.